NGEN
NervGen Pharma Corp. Common stock NASDAQ Listed Feb 8, 2021$2.09
Pre-mkt
$2.14
+2.50%
Mkt Cap $171.8M
52w Low $1.70
8.5% of range
52w High $6.30
50d MA $2.81
200d MA $3.57
P/E (TTM)
—
EV/EBITDA
—
P/B
43.5x
Debt/Equity
0.0x
ROE
—
P/FCF
-7.8x
RSI (14)
65.80
ATR (14)
$0.17
Beta
0.99
50d MA
$2.81
200d MA
$3.57
Avg Volume
1.4M
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
1455 Bellevue Avenue, Suite 301 · West Vancouver, BC V7T 1C3 · CA
Data updated apr 26, 2026 2:55pm
· Source: financialmodelingprep.com